NCT01495715撤回3 期
Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
研究概览
简要总结
The objective of the study is to determine whether administration of idebenone can shorten the time to improvement of visual acuity in patients with chronic vision loss due to LHON.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 10 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > or equal 10 years and < 65 years
- •Impaired visual acuity in affected eyes due to LHON: Visual acuity in best eye >0.4 logMAR
- •No explanation for visual loss besides LHON
排除标准
- •Any previous use of idebenone
- •Participation in another clinical trial of any investigational drug within 3 months prior to Baseline
- •Previous participation in Study SNT-II-003 (RHODOS) for idebenone.
研究组 & 干预措施
Idebenone
Experimental
干预措施: Idebenone (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
研究者
相似试验
已完成
2 期
Idebenone to Treat Friedreich's AtaxiaFriedreich AtaxiaNCT00229632National Institute of Neurological Disorders and Stroke (NINDS)51
已完成
2 期
Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic NeuropathyLeber's Hereditary Optic NeuropathyNCT00747487Santhera Pharmaceuticals85
终止
3 期
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid SteroidsDuchenne Muscular Dystrophy (DMD)NCT02814019Santhera Pharmaceuticals255
终止
3 期
Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)Duchenne Muscular DystrophyNCT03603288Santhera Pharmaceuticals161
已完成
3 期
Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's AtaxiaFriedreich's AtaxiaNCT00537680Santhera Pharmaceuticals70